Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Slides:



Advertisements
Similar presentations
Volume 61, Issue 5, Pages (May 2012)
Advertisements

Volume 72, Issue 3, Pages (September 2017)
An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer  Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco.
Volume 68, Issue 6, Pages (December 2015)
Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction? 
Volume 62, Issue 3, Pages (September 2012)
Volume 155, Issue 3, Pages (March 1996)
The PSA Era is not Over for Prostate Cancer
Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for.
Volume 50, Issue 1, Pages (July 2006)
Testosterone Therapy in Men With Prostate Cancer
Volume 53, Issue 4, Pages (April 2008)
The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients 
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
European Urology Oncology
Volume 49, Issue 2, Pages (February 2006)
Volume 61, Issue 5, Pages (May 2012)
Volume 53, Issue 5, Pages (May 2008)
Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database 
Volume 51, Issue 4, Pages (April 2007)
Volume 73, Issue 3, Pages (March 2018)
European Urology Oncology
Volume 52, Issue 4, Pages (October 2007)
Volume 63, Issue 6, Pages (June 2013)
Volume 68, Issue 5, Pages (November 2015)
Volume 67, Issue 2, Pages (February 2015)
Volume 53, Issue 4, Pages (April 2008)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Volume 74, Issue 2, Pages (August 2018)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 68, Issue 3, Pages (September 2015)
Laurent Boccon-Gibod  European Urology Supplements 
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 5, Pages (May 2012)
Volume 53, Issue 4, Pages (April 2008)
Volume 68, Issue 4, Pages (October 2015)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma  Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,
Prostate Cancer Nomograms: An Update
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
European Urology Oncology
European Urology Oncology
Volume 59, Issue 4, Pages (April 2011)
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
European Urology Oncology
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
European Urology is “Your” Journal
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Volume 50, Issue 5, Pages (November 2006)
Axel Heidenreich  European Urology Supplements 
Volume 54, Issue 1, Pages (July 2008)
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Axel Heidenreich  European Urology Supplements 
Volume 51, Issue 5, Pages (May 2007)
Salvage Local Treatments After Focal Therapy for Prostate Cancer
European Urology Oncology
European Urology Oncology
Presentation transcript:

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases  Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi, Francesco Montorsi, Shahrokh Shariat, Bernhard Grubmüller, Giorgio Gandaglia, Alberto Briganti, R. Jeffrey Karnes  European Urology Oncology  Volume 1, Issue 1, Pages 46-53 (May 2018) DOI: 10.1016/j.euo.2018.03.002 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Overall survival for the cohort of 113 patients. CE=cumulative number of events; NR=number at risk. European Urology Oncology 2018 1, 46-53DOI: (10.1016/j.euo.2018.03.002) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Clinical relapse-free survival. CE=cumulative number of events; NR=number at risk. European Urology Oncology 2018 1, 46-53DOI: (10.1016/j.euo.2018.03.002) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Overall survival according to serum PSA<0.1ng/ml versus >0.1ng/ml at 6 wk after surgery (p=0.0003). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen. European Urology Oncology 2018 1, 46-53DOI: (10.1016/j.euo.2018.03.002) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 4 PSA relapse-free survival according to preoperative PSA<1.0ng/ml versus 1.1–4.0ng/ml versus>4.1ng/ml (p=0.0004). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen. European Urology Oncology 2018 1, 46-53DOI: (10.1016/j.euo.2018.03.002) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 5 PSA relapse-free survival according to median preoperative PSA<8.0ng/ml versus >8.0ng/ml (p=0.002). CE=cumulative number of events; NR=number at risk; PSA=prostate-specific antigen. European Urology Oncology 2018 1, 46-53DOI: (10.1016/j.euo.2018.03.002) Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.